Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations

• A single 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in all patients evaluated• Results based on analyses of high-risk patients from RE-VERSE AD™ study• Data presented at ACC 2016 Scientific Session and Expo
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news